Source comparison
BPC-157 Cartalax Protocol: Research vs Application Comparison
BPC-157 Dose 250–500mcg/day subcutaneous, site-specific Injection proximity to joint often limited by tissue depth and anatomical safety Localized dosing shows 40% higher tissue concentration in animal models. Worth the technique complexity Cartalax Dose 10–20
This comparison does not assign a generated winner or score.
- BPC-157 Dose
- 250–500mcg/day subcutaneous, site-specific
- Injection proximity to joint often limited by tissue depth and anatomical safety
- Localized dosing shows 40% higher tissue concentration in animal models. Worth the technique complexity
- Cartalax Dose
- 10–20mg oral OR 1–2mg injectable every 48–72h
- Oral form easier but ~60% lower bioavailability than injectable
- Injectable form justified for research protocols demanding measurable mitochondrial changes
- Cycle Duration
- 4–8 weeks in rodent tendon studies
- Human tendon remodeling takes 12–16 weeks. Peptide protocols typically run first 6 weeks only
- Peptides accelerate early-phase repair; latter phase depends on mechanical loading and nutrition
- Monitoring
- Histology, tensile strength testing, imaging (ultrasound, MRI)
- Research settings track collagen organization; outside lab settings rely on symptom reduction
- Without imaging, impossible to distinguish pain reduction from actual tissue repair. Critical gap
- Washout Period
- 2–4 weeks between cycles in repeat-dose studies
- Unknown whether multiple cycles compound benefits or hit diminishing returns
- Current evidence supports single 6–8 week cycle; re-dosing protocols are speculative
- Bottom Line
- Rodent data strong; human data observational only
- Protocol shows mechanistic promise but lacks RCT validation for joint-specific outcomes
- Worth pursuing in research contexts with proper controls. Premature for clinical recommendation